Daytrana Patch
NDC Package 68968-5553-3
Package Information
Daytrana (methylphenidate) patches is dAYTRANA (methylphenidate transdermal system) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.Limitations of UseThe use of DAYTRANA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.8), Use in Specific Populations (8.4)]. This formulation utilizes a patch delivery system. Marketed by Noven Therapeutics, Llc, this product is identified by NDC 68968-5553 and is authorized under FDA application NDA021514.
Identification & Billing
- RxCUI: 753436 - methylphenidate 10 MG/9HR Transdermal System
- RxCUI: 753436 - 9 HR methylphenidate 1.11 MG/HR Transdermal System
- RxCUI: 753436 - methylphenidate 1.1 MG/HR 9HR Transdermal System
- RxCUI: 753436 - methylphenidate 10 MG per 9HR Transdermal Patch
- RxCUI: 753437 - Daytrana 10 MG/9HR Transdermal System
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68968 - Noven Therapeutics, Llc
- 68968-5553 - Daytrana
- 68968-5553-3 - 30 PATCH in 1 CARTON / 9 h in 1 PATCH
- 68968-5553 - Daytrana
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68968-5553-3 identifies a specific commercial package of 30 patch in 1 carton / 9 h in 1 patch of Daytrana, a human prescription drug labeled by Noven Therapeutics, Llc. This patch is formulated for transdermal use and contains methylphenidate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Noven Therapeutics, Llc on April 06, 2006. The current certification is valid through December 31, 2026.
How is this Noven Therapeutics, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68968555303. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.